Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 131,13 € (+26,70 %). La mediana es de 139,81 € (+35,08 %).
| Comprar |
22 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
AstraZeneca offers about $10 billion for Rhythm Pharmaceuticals
AstraZeneca has reportedly made a takeover offer of about $10 billion for Rhythm Pharmaceuticals, equivalent to $124 per share. Rhythm develops the drug IMCIVREE (active ingredient Setmelanotid) for rare causes of obesity and recorded $92.1 million in revenue in the third quarter, an increase of 29 percent from the previous quarter. Analysts see blockbuster potential for IMCIVREE, meaning AstraZeneca’s offer would strengthen its position in the metabolic field. » Más en deraktionaer.de
Rhythm Pharmaceuticals: launch of IMCIVREE for hypothalamic obesity gains momentum
Rhythm Pharmaceuticals said at the Wells Fargo conference that the launch of IMCIVREE for hypothalamic obesity is in the “second quarter” of rollout and that there are already about 400 prescriptions from roughly 300 physicians. The company sees hypothalamic obesity (HO), Bardet‑Biedl syndrome and Prader‑Willi syndrome as strategic growth areas and reported positive Phase II data in Prader‑Willi that support Phase III planning. Rhythm stressed it is well capitalized and does not need to raise funds in the near term, but cited access to endocrinologists and the need for multiple studies in Prader‑Willi as operational challenges. The company is also developing follow‑on programs (RM‑718, Bivamelagon) to strengthen the pipeline and long‑term competitive position. » Más en de.investing.com
Rhythm Pharmaceuticals receives Japanese approval for Imcivree to treat acquired hypothalamic obesity
Japan’s Ministry of Health, Labour and Welfare has approved Imcivree (setmelanotid) from Rhythm Pharmaceuticals for the treatment of acquired hypothalamic obesity, the first approved therapy for this form in Japan. Rhythm estimates the patient population in Japan at 5,000–8,000 and plans to launch the product before the end of 2026, depending on pricing. The approval is based on the phase‑3 TRANSCEND study, which showed a placebo‑adjusted BMI reduction of 18.8%; Imcivree is already approved in the US and the EU. » Más en de.investing.com
Rhythm Pharmaceuticals: US launch of IMCIVREE gains momentum
Rhythm reports that the US launch of IMCIVREE for acquired hypothalamic obesity is showing strong early demand, with more than 400 therapy requests in 14 weeks and prescriptions from over 300 physicians. About two-thirds of requests were approved by quarter-end; coverage policies account for roughly 25% of commercially insured and 35% of Medicaid beneficiaries. The company holds about $330 million in cash, sufficient for roughly 24 months, and does not see a near-term need for an equity raise. Rhythm is also advancing a pipeline of MC4R agonists, plans Phase III strategies for Prader-Willi before the end of 2025, and intends to further develop bivamelagon and other programs globally. » Más en de.investing.com
Rhythm Pharmaceuticals: positive Phase 2 data for RM-718 show 11.6% average BMI reduction
Rhythm Pharmaceuticals reports preliminary Phase 2 results for the once‑weekly MC4R agonist RM‑718 in 11 patients with acquired hypothalamic obesity. Seven patients who completed 16 weeks showed an average BMI reduction of 11.6%, stronger than comparator values for bremelanotide (bivamelagon) (10.1% after 14 weeks) and setmelanotide (10.1% after 16 weeks). There were two mild cases of local hyperpigmentation at the injection site and common adverse events such as injection‑site reactions, nausea and vomiting; two patients discontinued due to adverse events. RM‑718 is designed for high selectivity with sparing of MC1R to reduce hyperpigmentation. Rhythm will hold a conference call on Q2 financial results. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 81,34 M | 86,07 % |
| Beneficio bruto | 70,59 M | 80,89 % |
| Beneficio neto | -36,52 M | 18,98 % |
| EBITDA | -32,02 M | 21,31 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 7239,84 M € |
Número de acciones | 69,33 M |
Máximo/mínimo de 52 semanas | 110,94 € - 67,64 € |
| Dividendos | No |
Beta | 2,13 |
Ratio P/E | -39,66 |
Ratio PEG | -6,20 |
Ratio P/B | 39,40 |
Ratio P/S | 28,40 |
Perfil de la empresa
Rhythm Pharmaceuticals, Inc., una empresa biofarmacéutica en fase comercial, se centra en el desarrollo y la comercialización de terapias para el tratamiento de enfermedades genéticas raras de obesidad. El principal candidato a producto de la compañía es IMCIVREE, un potente receptor de melanocortina-4 para el tratamiento de la obesidad por deficiencia de pro-opiomelanocortina (POMC), de proproteína convertasa subtilisina/kexina tipo 1, de receptor de leptina (LEPR), así como de los síndromes de Bardet-Biedl y de Alström. También está desarrollando setmelanotida, que se encuentra en ensayos clínicos de fase II para el tratamiento de las obesidades por deficiencia heterocigótica de POMC o LEPR, la obesidad por deficiencia del coactivador 1 de receptores de esteroides, la obesidad por deficiencia de SH2B1, la obesidad por deficiencia del receptor MC4, la obesidad del síndrome de Smith-Magenis, los trastornos epigenéticos de POMC y otros trastornos relacionados con MC4R. Rhythm Pharmaceuticals, Inc. mantiene un acuerdo de investigación colaborativa con el Registro Clínico para la Investigación del Síndrome de Bardet-Biedl. La compañía era anteriormente conocida como Rhythm Metabolic, Inc. y cambió su nombre a Rhythm Pharmaceuticals, Inc. en octubre de 2015. Rhythm Pharmaceuticals, Inc. fue fundada en 2008 y tiene su sede en Boston, Massachusetts.
| Nombre | Rhythm Pharmaceuticals Inc |
| CEO | David Meeker |
| Sede | Boston,
ma Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 09/10/2017 |
| Empleados | 414 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | RYTM |
Frankfurt | 1RV.F |
Düsseldorf | 1RV.DU |
München | 1RV.MU |